ICON Public (NASDAQ:ICLR - Get Free Report)'s stock had its "outperform" rating restated by research analysts at William Blair in a research note issued on Tuesday,Benzinga reports.
Other equities research analysts have also issued research reports about the stock. Citigroup dropped their price objective on shares of ICON Public from $300.00 to $290.00 and set a "buy" rating for the company in a research report on Monday, January 6th. Baird R W downgraded ICON Public from a "strong-buy" rating to a "hold" rating in a report on Thursday, October 24th. StockNews.com cut ICON Public from a "buy" rating to a "hold" rating in a research note on Thursday, September 19th. Evercore ISI lowered their target price on ICON Public from $360.00 to $350.00 and set an "outperform" rating for the company in a research note on Tuesday, October 8th. Finally, Robert W. Baird reduced their price target on ICON Public from $249.00 to $225.00 and set a "neutral" rating on the stock in a research report on Wednesday, November 20th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, ICON Public presently has an average rating of "Moderate Buy" and an average price target of $287.00.
Check Out Our Latest Analysis on ICON Public
ICON Public Trading Down 8.1 %
Shares of ICLR traded down $17.75 during trading hours on Tuesday, hitting $200.24. The stock had a trading volume of 1,830,683 shares, compared to its average volume of 899,485. ICON Public has a 12-month low of $183.38 and a 12-month high of $347.72. The firm has a market cap of $16.52 billion, a P/E ratio of 22.32, a P/E/G ratio of 1.54 and a beta of 1.20. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34. The company's fifty day simple moving average is $211.31 and its 200 day simple moving average is $270.81.
ICON Public (NASDAQ:ICLR - Get Free Report) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts' consensus estimates of $3.72 by ($0.37). The firm had revenue of $2.03 billion during the quarter, compared to analysts' expectations of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The business's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter last year, the business earned $3.10 earnings per share. Equities research analysts forecast that ICON Public will post 13.42 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of ICLR. Foyston Gordon & Payne Inc acquired a new position in ICON Public in the third quarter valued at approximately $11,672,000. Icon Wealth Advisors LLC boosted its position in ICON Public by 861.1% during the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company's stock valued at $3,797,000 after purchasing an additional 11,840 shares during the period. Whittier Trust Co. grew its stake in ICON Public by 12.3% during the 3rd quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company's stock worth $1,155,000 after buying an additional 441 shares during the last quarter. Sara Bay Financial acquired a new stake in ICON Public in the third quarter worth $1,143,000. Finally, Steph & Co. lifted its stake in ICON Public by 3.7% in the fourth quarter. Steph & Co. now owns 1,560 shares of the medical research company's stock valued at $327,000 after buying an additional 55 shares during the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.
ICON Public Company Profile
(
Get Free Report)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Further Reading
Before you consider ICON Public, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICON Public wasn't on the list.
While ICON Public currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
